[Pfizer's CFO stepping down in August](https://www.cnbc.com/2026/06/18/pfizer-cfo-dave-denton-to-step-down-in-august.html) is being framed as routine succession planning. It's not. Mid-cycle finance chief exits in pharma happen when discount rates spike and long-dated cash flow models break—exactly what [Warsh's hawkish hold](https://www.cnbc.com/2026/06/17/warsh-fed-meeting-stock-market.html) created yesterday. The 10-year is at 4.49%, and PFE's pipeline is backend-loaded.

Research these companies